Thalidomide C1 selectively inhibits growth of tumorigenic liver progenitor cells.
Growth inhibition was achieve through the induction of apoptosis in treated cells.
Thalidomide C1 treatment did not consistently alter ERK signalling.
However non-canonical NFκB signalling consistently decreased following treatment.